Katharina Leucht

Jena, TH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Treatment of metastatic hormone-sensitive prostate cancer

Treatment of metastatic hormone-sensitive prostate cancer

Journal: Urologie (Heidelberg, Germany)

Published: February 13, 2026

Diagnostic Value of PSMA-PET/CT for the Detection of Pelvic Lymph Node Metastasis in Intermediate- and High-Risk Prostate Cancer.

Diagnostic Value of PSMA-PET/CT for the Detection of Pelvic Lymph Node Metastasis in Intermediate- and High-Risk Prostate Cancer.

Journal: Urologia internationalis

Published: February 02, 2026

Treatment of non-muscle-invasive bladder cancer

Treatment of non-muscle-invasive bladder cancer

Journal: Urologie (Heidelberg, Germany)

Published: January 06, 2026

Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning.

Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 28, 2025

Retrospective Analysis of Vesicourethral-Anastomosis Stricture/Urethral Stricture After Robotic-Assisted Laparoscopic Radical Prostatectomy With and Without Radiotherapy.

Retrospective Analysis of Vesicourethral-Anastomosis Stricture/Urethral Stricture After Robotic-Assisted Laparoscopic Radical Prostatectomy With and Without Radiotherapy.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: July 21, 2025

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

Journal: British journal of cancer

Published: July 02, 2025

Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC.

Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC.

Journal: ESMO open

Published: May 12, 2025

Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa.

Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 18, 2024

Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma

Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma

Journal: Urologie (Heidelberg, Germany)

Published: November 13, 2024

Complications of Tumor Nephrectomy with and Without Tumor Thrombus in the Vena Cava, Recorded with the Clavien-Dindo Classification: A Matched-Pair Analysis.

Complications of Tumor Nephrectomy with and Without Tumor Thrombus in the Vena Cava, Recorded with the Clavien-Dindo Classification: A Matched-Pair Analysis.

Journal: Cancers

Published: September 02, 2024

Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.

Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: May 09, 2024

Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC.

Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC.

Journal: Cancers

Published: April 23, 2024

Showing 1-12 of 35

Last Updated: 09/26/2026